Merus (NASDAQ:MRUS - Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $44.58, but opened at $46.23. Merus shares last traded at $45.76, with a volume of 24,734 shares traded.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on MRUS. StockNews.com cut shares of Merus from a "hold" rating to a "sell" rating in a research note on Monday, March 4th. Truist Financial began coverage on shares of Merus in a research note on Thursday, March 28th. They issued a "buy" rating and a $69.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Merus from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Thursday, February 29th. BMO Capital Markets lifted their price objective on shares of Merus from $49.00 to $58.00 and gave the stock an "outperform" rating in a research note on Thursday, February 29th. Finally, Stifel Nicolaus raised their target price on shares of Merus from $40.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $53.55.
Read Our Latest Stock Report on MRUS
Merus Price Performance
The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of -14.65 and a beta of 1.10. The firm's fifty day moving average is $43.94 and its 200 day moving average is $31.71.
Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.38). The company had revenue of $8.94 million for the quarter, compared to analyst estimates of $10.43 million. Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. Equities research analysts forecast that Merus will post -3.29 EPS for the current fiscal year.
Institutional Trading of Merus
A number of institutional investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC lifted its stake in Merus by 37.7% in the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 343 shares during the last quarter. California State Teachers Retirement System lifted its stake in Merus by 2.1% in the first quarter. California State Teachers Retirement System now owns 26,440 shares of the biotechnology company's stock valued at $486,000 after acquiring an additional 539 shares during the last quarter. Vanguard Group Inc. lifted its stake in Merus by 0.5% in the first quarter. Vanguard Group Inc. now owns 120,889 shares of the biotechnology company's stock valued at $3,196,000 after acquiring an additional 638 shares during the last quarter. Tudor Investment Corp Et Al raised its position in shares of Merus by 3.1% in the third quarter. Tudor Investment Corp Et Al now owns 23,638 shares of the biotechnology company's stock valued at $557,000 after purchasing an additional 716 shares during the period. Finally, Citigroup Inc. raised its position in shares of Merus by 29.4% in the fourth quarter. Citigroup Inc. now owns 3,530 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 803 shares during the period. 96.14% of the stock is currently owned by institutional investors and hedge funds.
About Merus
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Recommended Stories
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
